This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Byron U. Musa, MD
Oregon Medical Group Eugene

JAMA. 1994;272(16):1252.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Dr Ross-Degnan and colleagues¹ are to be commended for bringing to the attention of physicians the unfortunate results of drug company marketing on the prescribing practices of US physicians.

However, the logic of Ross-Degnan et al weakens when they state that the risks of drugs substituted for a drug withdrawn because of unanticipated bad effects should be considered before withdrawing the drug. The drug would not have been released if the bad effects had been known beforehand. Therefore, patients who needed to be treated for conditions for which the drug was putatively indicated would have been given the substituted drugs as first choice. Ergo, no net effect. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?